Report on the eligibility requirements for the Medicaid program administered by the Department of Human Services for the period July 1, 2006 through December 31, 2008

Report on the eligibility requirements for the Medicaid program administered by the Department of Human Services for the period July 1, 2006 through December 31, 2008

Report on the IowaCare program administered by the Iowa Medicaid Enterprise, a division of the Department of Human Services (DHS-IME), for the period July 1, 2005 through June 30, 2009

Report on the IowaCare program administered by the Iowa Medicaid Enterprise, a division of the Department of Human Services (DHS-IME), for the period July 1, 2005 through June 30, 2009

Atrial natriuretic peptide administered as intravenous infusion or bolus injection to patients with liver cirrhosis and ascites.

The effect of a synthetic atrial natriuretic peptide (h-ANP, 25 amino acids, Wy-47.663) on blood pressure, renal electrolyte excretion, plasma catecholamines, and plasma renin activity was studied in nine patients with cirrhosis of the liver and ascites. The peptide was infused intravenously at 24-h intervals for 2 h in groups of four patients each in two different doses (0.015 and 0.075 micrograms/kg/min or 0.06 and 0.3 micrograms/kg/min). A control experiment with the vehicle was performed in all patients. In three patients h-ANP (1 and 2 micrograms/kg i.v.) was administered as an intravenous bolus injection. Consistent falls in blood pressure were observed during h-ANP infusion only with the two higher doses. The two lower infused doses induced a consistent natriuresis; this renal response was abolished when the two larger doses were used. When given as a bolus, h-ANP had a natriuretic effect comparable to that of the two lower doses of infused h-ANP. Plasma catecholamines and plasma renin activity increased during infusion of the two higher doses of h-ANP. It thus appears that in patients with cirrhosis and ascites, the natriuretic effect of infused h-ANP decreases rather than increases when the doses are raised. Bolus administration of h-ANP may be less prone to trigger counterbalancing responses and side-effects.

Report on the Juvenile Detention Home Fund administered by the Department of Human Services for the period July 1, 2007 through November 10, 2009

Report on the Juvenile Detention Home Fund administered by the Department of Human Services for the period July 1, 2007 through November 10, 2009

Report on the Local Public Health Services Grant administered by the Bureau of Local Public Health Services, a division of Health Promotion and Chronic Disease Prevention of the Iowa Department of Public Health for the period July 1, 2006 through June 30, 2008

Report on the Local Public Health Services Grant administered by the Bureau of Local Public Health Services, a division of Health Promotion and Chronic Disease Prevention of the Iowa Department of Public Health for the period July 1, 2006 through June 30, 2008

Report on the Charter Agency Initiative administered by the Department of Management for the period July 1, 2003 through June 30, 2008

Report on the Charter Agency Initiative administered by the Department of Management for the period July 1, 2003 through June 30, 2008

Report on a review of the Fuel Inspection Program administered by the Iowa Department of Agriculture and Land Stewardship for the period July 1, 2005 through June 30, 2009

Report on a review of the Fuel Inspection Program administered by the Iowa Department of Agriculture and Land Stewardship for the period July 1, 2005 through June 30, 2009

Report on the Iowa Early Intervention Block Grant Program administered by the Department of Education for the period July 1, 2005 through June 30, 2010

Report on the Iowa Early Intervention Block Grant Program administered by the Department of Education for the period July 1, 2005 through June 30, 2010

Audit report on Highway Safety Projects administered by The Integer Group Midwest for the year ended September 30, 2007

Audit report on Highway Safety Projects administered by The Integer Group Midwest for the year ended September 30, 2007

Audit report on Highway Safety Projects administered by The Integer Group Midwest for the year ended September 30, 2008

Audit report on Highway Safety Projects administered by The Integer Group Midwest for the year ended September 30, 2008

Audit report on Highway Safety Projects administered by The Integer Group Midwest for the year ended September 30, 2009

Audit report on Highway Safety Projects administered by The Integer Group Midwest for the year ended September 30, 2009

Report on a review of the Boiler and Pressure Vessel Safety Program and the Elevator and Escalator Safety Program administered by Iowa Workforce Development for the period July 1, 2008 through June 30, 2010

Report on a review of the Boiler and Pressure Vessel Safety Program and the Elevator and Escalator Safety Program administered by Iowa Workforce Development for the period July 1, 2008 through June 30, 2010

Audit report on Highway Safety Projects administered by The Integer Group Midwest for the year ended September 30, 2010

Audit report on Highway Safety Projects administered by The Integer Group Midwest for the year ended September 30, 2010

Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination.

Methylphenidate and 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') are widely misused psychoactive drugs. Methylphenidate increases brain dopamine and norepinephrine levels by blocking the presynaptic reuptake transporters. MDMA releases serotonin, dopamine and norepinephrine through the same transporters. Pharmacodynamic interactions of methylphenidate and MDMA are likely. This study compared the pharmacodynamic and pharmacokinetic effects of methylphenidate and MDMA administered alone or in combination in healthy subjects using a double-blind, placebo-controlled, crossover design. Methylphenidate did not enhance the psychotropic effects of MDMA, although it produced psychostimulant effects on its own. The haemodynamic and adverse effects of co-administration of methylphenidate and MDMA were significantly higher compared with MDMA or methylphenidate alone. Methylphenidate did not change the pharmacokinetics of MDMA and vice versa. Methylphenidate and MDMA shared some subjective amphetamine-type effects; however, 125 mg of MDMA increased positive mood more than 60 mg of methylphenidate, and methylphenidate enhanced activity and concentration more than MDMA. Methylphenidate and MDMA differentially altered facial emotion recognition. Methylphenidate enhanced the recognition of sad and fearful faces, whereas MDMA reduced the recognition of negative emotions. Additionally, the present study found acute pharmacodynamic tolerance to MDMA but not methylphenidate. In conclusion, the combined use of methylphenidate and MDMA does not produce more psychoactive effects compared with either drug alone, but potentially enhances cardiovascular and adverse effects. The findings may be of clinical importance for assessing the risks of combined psychostimulant misuse. Trial registration identification number: NCT01465685 (http://clinicaltrials.gov/ct2/show/NCT01465685).